Welcome to our dedicated page for Delcath Sys news (Ticker: DCTH), a resource for investors and traders seeking the latest updates and insights on Delcath Sys stock.
Delcath Systems Inc (NASDAQ: DCTH) specializes in innovative liver cancer therapies through its proprietary drug-device combination. This page provides investors and medical professionals with direct access to all official company announcements, including clinical trial milestones, regulatory updates, and strategic partnerships.
Discover the latest developments in Delcath's hepatic delivery system and melphalan hydrochloride treatments. Our curated news collection features FDA communications, European commercialization progress, and peer-reviewed research findings – essential resources for understanding the company's position in interventional oncology.
Key updates on: Clinical trial phases | Regulatory approvals | Financial results | Medical conference presentations | Partnership announcements. Bookmark this page to monitor Delcath's advancements in targeted chemotherapy delivery and liver cancer treatment protocols.
Delcath Systems (NASDAQ: DCTH) announced an amendment to its loan agreement with Avenue Venture Opportunities Fund, allowing for an interest-only period from
Delcath Systems, Inc. (Nasdaq: DCTH) has completed a $25 million private placement with the potential for an additional $60 million based on milestone achievements. The financing, led by Vivo Capital and supported by various investors, is intended to fund operations through the anticipated FDA PDUFA date of August 14, 2023 for its product HEPZATO. The total proceeds are expected to cover working capital and general corporate purposes, with warrants providing further potential funding. The deal enables funding for commercialization if HEPZATO receives approval.
FAQ
What is the current stock price of Delcath Sys (DCTH)?
What is the market cap of Delcath Sys (DCTH)?
